All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Bioharmony Therapeutics Inc., a New York-based startup developing lysins to fight bacterial infections, has secured support from Boehringer Ingelheim International GmbH to develop a therapy for multidrug-resistant Acinetobacter infections, a frequent cause of hospital-acquired pneumonia, blood and wound infections. Financial terms of the licensing and collaboration deal, arranged by Boehringer's Research Beyond Borders (RBB) program, were not disclosed.